TD Waterhouse Canada Inc. Grows Stock Position in Solventum Corporation $SOLV

TD Waterhouse Canada Inc. raised its holdings in Solventum Corporation (NYSE:SOLV) by 1,414.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 24,990 shares of the company’s stock after acquiring an additional 23,340 shares during the period. TD Waterhouse Canada Inc.’s holdings in Solventum were worth $1,958,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. BOKF NA lifted its holdings in Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after acquiring an additional 141 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Solventum by 23.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock valued at $60,000 after purchasing an additional 142 shares during the period. NewEdge Advisors LLC grew its stake in shares of Solventum by 2.2% in the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock worth $438,000 after acquiring an additional 144 shares in the last quarter. Deseret Mutual Benefit Administrators raised its position in Solventum by 39.5% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 516 shares of the company’s stock valued at $41,000 after purchasing an additional 146 shares in the last quarter. Finally, HB Wealth Management LLC raised its holdings in Solventum by 3.5% in the first quarter. HB Wealth Management LLC now owns 4,292 shares of the company’s stock valued at $280,000 after acquiring an additional 147 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SOLV shares. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research report on Saturday, August 22nd. Mizuho set a $113.00 price target on Solventum in a research note on Thursday, August 6th. KeyCorp raised their price objective on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Finally, Stifel Nicolaus raised their price objective on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Solventum currently has an average rating of “Moderate Buy” and a consensus target price of $91.64.

Solventum Price Performance

Solventum stock opened at $90.21 on Wednesday. The firm has a fifty day moving average of $84.53 and a 200-day moving average of $76.25. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $94.16. The firm has a market capitalization of $15.36 billion, a P/E ratio of 11.03, a PEG ratio of 1.43 and a beta of 0.61.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.64. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, analysts predict that Solventum Corporation will post 7.22 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.